Nabriva Therapeutics PLC (NASDAQ:NBRV)
| 0.1821 Delayed Data As of Aug 09 |  -0.0069 / -3.65%Today’s Change | 0.16 Today|||52-Week Range 1.40 | -69.59% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 2 2018 | Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | |||
| Revenue and Income | Net Revenues | 847.0K | 461.0K | 797.0K | 1.7M | |
| Depreciation And Amortization | 129.0K | 129.0K | 119.0K | 234.0K | ||
| Operating Expenses | Gross Income | -- | -- | -- | -- | -- |
| General Expenses | 18.4M | 21.3M | 31.4M | 20.7M | ||
| Research And Development | 9.7M | 8.9M | 21.4M | 7.5M | ||
| Total Operating Expenses | 18.6M | 21.5M | 31.6M | 20.9M | ||
| Non-Operating Expenses | Operating Income | -17.7M | -21.0M | -30.8M | -19.2M | |
| Extraordinary Charge | 0.00 | -31.9M | -118.0K | 0.00 | ||
| Interest Expense On Debt | 7.0K | 8.0K | 114.0K | 899.0K | ||
| Other Expenses | -141.0K | -54.0K | -100.0K | 70.0K | ||
| Income Taxes, Minority Interest and Extra Items | Pre-Tax Income | -17.8M | -53.0M | -31.1M | -20.1M | |
| Income Taxes | -48.0K | -151.0K | -258.0K | -154.0K | ||
| Net Income | -17.8M | -52.8M | -30.8M | -20.2M | ||
| Shares To Calculate EPS | Shares To Calculate EPS | 40.5M | 58.4M | 67.0M | 68.7M | |
| Shares To Calculate EPS Diluted | 40.5M | 58.4M | 67.0M | 68.7M | ||
| Earnings Per Share | EPS | -$0.44 | -$0.90 | -$0.41 | -$0.29 | |
| EPS Diluted | -$0.44 | -$0.90 | -$0.46 | -$0.29 | ||
